Ioannis Syrios MEDICAL ONCOLOGY

¨DNA ploidy and other factors affecting overall survival in patients with advanced gastric adenocarcinoma¨ Medical School, University of Athens, Greece 05.2007- 06.2012

• ESMO
• G.Y.ON (Young Medical Oncologists Working Group)
• General Medical Council –Specialist registration (από 16/05/2013)
• Hellenic Society of Medical Oncology (HESMO), Greek Cancer Society
• Hellenic Cooperative Oncology Group (HeCOG)
• Hellenic Oncology Research Group (HORG)
• Fertility Preservation in Cancer Patients (GONEAS)

Editorial Boards

• Editorial Board Member in “Journal of Balkan Union of Oncology”
• AD-HOC REVIEWER for peer-reviewed international journals: “Annals of Oncology”, “Br J Surg”, “AJPP”

• 01.02.2016 – today Medical Oncologist YGEIA & MITERA Hospital
• 30.01.2014 – 30.01.2016 Consultant Medical Oncologist, 2nd Department of Medical Oncology, “Saint Savvas” Cancer Hospital, Athens, Greece
• 08.07.2013 – 08.01.2014 Clinical Research Fellow in Gynae/Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom
• 29.03.2013 – 29.05.2013 Medical Oncologist, 1st Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece
• 29.03.2009 – 29.03.2013 Resident Doctor in Medical Oncology, 1st Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece
• 06.2008-12.2008 Resident Doctor in Hematology, Department of Pathophysiology, Medical School, University of Athens, Greece
• 06.2006-06.2008 Resident Doctor in Internal Medicine, 1st Department of Internal Medicine, Asclepeion General Hospital, Athens, Greece
• 12.2005-03.2010 Research associate Doctor in Medical Oncology, Department of Pathophysiology, Medical School, University of Athens, Greece
• 12.2004-08.2005 Compulsory military service as a Sergeant Doctor, Hellenic Army, Air Force
• 08.2003-08.2004 Rural Doctor at the Health Center of Dimitsana, Arkadia, Greece 
• 05.2004-08.2004 Rural Doctor at the General Regional Hospital of Tripolis, Greece

Education Experience

• Tutor in the Hellenic Boards of Oncology 2014
• Professor of Medical Anatomy and Physiology in Medical Imaging Devices Faculty, Public Institute of Professional Training, Markopoulo, Attiki, Greece 2005–2006

Clinical Interest: 

• Gynecological Oncology & Breast Cancer
• Urogenital Cancer
• Gastrointestinal Cancer
• Lung Cancer
• High dose chemotherapy with autologous stem cell support in solid tumors
• Fertility preservation in cancer patients 

Research Interest: 

• Phase I-II-III Clinical trials in Gynecological Oncology, PARP and immune checkpoint inhibitors in epithelial Ovarian Cancer, Anti-angiogenesis in gynecological tumors. 
• Leader member in Gynaecological Oncology Research Group in the Hellenic Oncology Research Group (HORG) and Hellenic Cooperative Oncology Group (HeCOG)

• Prize for the best oral presentation “Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study” 7th Congress of Balkan Union of Oncology, Kusadasi, Turkey, 15-19 October 2008
• Scholarship granted by the Hellenic Society of Medical Oncology (HeSMO), 2013 
• Scholarship granted by the European School of Oncology (ESO), 2013

• “Gastric Cancer: From Staging to Surgical Treatment. Procedures, Complications and Oncological Results” NOVA publishers ISBN: 978-1-62081-294-5 Chapter 3: Surgical Treatment of Early and Advanced Disease and Prognostic Factors
• ¨CRITICAL CARE AND EMERGENCY MEDICINE: MONITORING¨ Pashalidis Editions, Athens 2009 Lung Cancer Monitoring Chapter

• Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. Rare Tumors. 2017 Oct 3;9(3):7016
• An ovarian mature cystic teratoma evolving in squamous cell carcinoma: A case report and review of the literature. Gynecol Oncol Rep. 2016 Dec 18;19:27-30
• Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non small cell lung cancer patients. Mol Clin Oncol. 2016 Oct;5(4):440-446. 
• Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2015 Aug;15(8):875-84. 
• Thymic carcinoma: what after disease progression? J BUON 2014; 19(2): 577-584. 
• Advances in thymic carcinoma diagnosis and treatment: a review of literature. Med Oncol. 2014 Jul;31(7):44. 
• Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are we Now? Anticancer Res. 2014 May;34(5):2069-77. 
• Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. BMC Nephrol. 2013 Apr 12;14(1):84. 
• DNA ploidy: a prognostic factor of response to chemotherapy and survival in metastatic gastric adenocarcinoma. Anticancer Res. 2013 Mar;33(3):1209-1214
• Cutaneous metastasis from hepatocellular carcinoma. J BUON. 2012 Oct;17(4):797-798.